240 WAY-102: an <i>in vivo</i> lentiviral dual-armored CLDN18.2 CAR T engineered for long-term durability &amp; cytotoxicity in the tumor microenvironment

Cassandra Kontur(Bridgepoint (United States)), David V. Phizicky(Bridgepoint (United States)), Reeti Sanghrajka(Bridgepoint (United States)), Gundula Povysil(Bridgepoint (United States)), Annie Dyatel(Bridgepoint (United States)), Liang He(Ruijin Hospital), Xinchen Wang(Columbia University Irving Medical Center), Stephen Pu(Bridgepoint (United States)), Megha Sah(Bridgepoint (United States)), Ujas A. Patel(Bridgepoint (United States))
Regular and Young Investigator Award Abstracts
November 1, 2025
Cited by 0


Related Papers